BlossomHill Therapeutics Reports Results for Quarter Ended June 30, 2026

What Happened

• On September 18, 2026, BlossomHill Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release. The press release is attached to the company's Form 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: September 18, 2026 (Form 8-K, Item 2.02).
• Reporting period: quarter ended June 30, 2026.
• Disclosure format: press release attached as Exhibit 99.1; Interactive XBRL cover page included (Exhibit 104).
• The 8-K furnishes the press release announcing the company’s quarterly financial results; investors should review Exhibit 99.1 for detailed figures and commentary.

Why It Matters

• This 8-K signals that BlossomHill has publicly released its latest quarterly earnings and related financial information. Retail investors should read the attached press release to see revenue, profit/loss, cash position, any updated guidance or management commentary, and to assess near-term prospects. The Form 8-K itself does not add additional corporate actions or executive changes beyond the earnings disclosure.